Single-agent gemcitabine is active in previously treated metastatic breast cancer. - Wikidata - awgldk - TriplyDB

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

http://www.wikidata.org/entity/Q33337761

about

First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.Gemcitabine-oxaliplatin combination in heavily pretreated metastatic breast cancer: a pilot study on 43 patients.Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.Phase II study of oxaliplatin plus leucovorin and 5-fluorouracil in heavily pretreated metastatic breast cancer patients.A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.Factors responsible for long-term survival in metastatic breast cancer.A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study.Gemcitabine in metastatic breast cancer.Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.Role of gemcitabine in cancer therapy.Gemcitabine enhances antitumor efficacy of recombinant lipoimmunogen-based immunotherapy.Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane- pretreated metastatic breast cancer.Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: retrospective analysis of 124 patients.Eribulin (Halaven): a new, effective treatment for women with heavily pretreated metastatic breast cancer.Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more.Is gemcitabine cost effective in cancer treatment?Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancer.Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up.Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

P2860

Q24812405-F1BD605B-1C58-4C00-BF65-229A320FB000 Q33244593-06165A10-CD48-4209-94ED-F95C67DADA65 Q33373017-1E86EE43-0273-4788-BCF0-7414BF2947EF Q33374338-E8CB97CD-90FE-42F9-97C9-D43816EE5038 Q33374977-7AACF94D-599D-4073-91CD-D089435E33D2 Q33378298-8352F3C7-4D53-4117-A0F6-1577D4BC7B3B Q33379805-D1619CBA-EBAE-43D8-9FD3-F4EED037DA5B Q33393809-125A01BE-D5A5-42E7-8D9F-9E0086F6FCC6 Q33394017-20E933A2-9D99-4263-A9CD-DE0645FBCCE9 Q33423308-5E6FBA28-BC69-4319-A587-CF6E17FE3063 Q33432594-BEE40570-A096-4BC1-A56F-C8CBCF098D9B Q33441161-45177BE8-4971-4EA6-874C-319A31ABD764 Q34395614-15DD70EC-8332-4912-BBBC-B0CA4BD78B8D Q34537146-690EB823-8877-4812-80EC-A39FE49F3E84 Q34618606-A222FDFF-664B-404C-B42D-4CE4229C7248 Q34746035-74935635-80EE-4C72-9F42-92FC1427CA02 Q36153748-1D4FE8D4-345F-47C3-9322-48DB5CD8117E Q36185611-D20D1605-8407-4B06-95CC-FA00B4FDA2ED Q36195491-E8862BA3-D166-449A-ABCB-B2364D0E6904 Q36429373-1D8E6D40-3BE8-425D-81D9-D4035CE8AD41 Q36821133-0474E52F-69A2-4D5B-BE80-EC4DBBE5A521 Q37230098-95DCA844-0ED9-4AE1-B83D-5EE896628739 Q37341664-50F75530-D2E4-4484-A602-DBDCE9DD30E8 Q37356090-FDEE383B-715A-4F41-9A8B-6B90222C06B1 Q37641082-1C1F84BF-4D97-4A77-8B52-23FB7B3EB92F Q43042833-64DFA43F-5AD0-466D-BB5E-08869524DF1B Q43267072-ECCC68EA-7D4A-46F7-A830-BD5AEC220668 Q44010183-5F0A4E13-DDAF-499F-BED9-0E92A3825773 Q44982988-6E4407FA-9C41-403E-A21C-7C40ADFC13C5 Q46727663-6D99FCC3-7030-4ECA-A4BF-F54BDE562660 Q55054679-B1CDAB2B-D5EF-4894-A52F-6F3D2515DD50

P2860

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

http://www.wikidata.org/entity/Q33337761

description

2001 nî lūn-bûn

@nan

2001 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@ast

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@en

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@nl

type

label

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@ast

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@en

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@nl

prefLabel

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@ast

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@en

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@nl

P1433

Q33337761-3E04CF5C-A31B-4306-998C-E49A6EEF739F

P1476

Q33337761-C8B715E8-FB3F-47AA-99F9-7DEE4AECC09F

P2093

Q33337761-09174620-F1AE-4C9F-B636-DDA35BF1E9C3

Q33337761-19094438-DA56-4582-849A-45BA9369451C

Q33337761-37C5BEF9-4BF1-4285-96E3-2CE0632EE215

Q33337761-4085D030-870B-491D-836F-72CCC91E0E36

Q33337761-436139DB-0735-47A4-92E8-B14E37BBDD37

Q33337761-753DADD8-FFCA-4E3C-9D7E-57CBADA48028

Q33337761-78376459-9F25-4C46-B167-1F39B9F66C39

Q33337761-7D4A6450-9B37-4387-BE78-DF940000C88F

Q33337761-A365CC77-87CC-4B08-BE3E-97658025FCAE

Q33337761-A767D2A0-6762-41D5-85DF-4F62C4AA3567

P304

Q33337761-3E72B8F6-4464-4AB7-A7E2-8D2236827976

P31

Q33337761-07F90083-8437-40BD-9B48-5C16640D55F0

P356

Q33337761-6CDDB0AB-1B9E-42B9-96A8-48005D9D7CBE

P433

Q33337761-5585D044-79C5-4EA3-ABBB-B33DFBF50BCA

P478

Q33337761-3960A699-F6FB-4B20-9ADF-6CE7152705BE

P577

Q33337761-6F27BB26-0F42-41E1-8C85-7325A51D33B4

P698

Q33337761-E7C09027-59A7-40C9-AF36-55F5384D338E

P356

P1433

P1476

Single-agent gemcitabine is active in previously treated metastatic breast cancer.

@en

P2093

A Llombart-Cussac

http://www.w3.org/2001/XMLSchema#string

A Ponzio

http://www.w3.org/2001/XMLSchema#string

C Cuvier

http://www.w3.org/2001/XMLSchema#string

G Perrocheau

http://www.w3.org/2001/XMLSchema#string

J M Ferrero

http://www.w3.org/2001/XMLSchema#string

L Kayitalire

http://www.w3.org/2001/XMLSchema#string

M Espié

http://www.w3.org/2001/XMLSchema#string

M Namer

http://www.w3.org/2001/XMLSchema#string

M Spielmann

http://www.w3.org/2001/XMLSchema#string

P Fumoleau

http://www.w3.org/2001/XMLSchema#string

P304

303-307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000058524

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P577

2001-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11408796

http://www.w3.org/2001/XMLSchema#string